ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

BVX Bivictrix Therapeutics Plc

11.25
-0.50 (-4.26%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Bivictrix Therapeutics Plc LSE:BVX London Ordinary Share GB00BNXH3K91 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50 -4.26% 11.25 10.50 12.00 11.75 11.25 11.75 34,569 15:25:58
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 0 -2.5M -0.0303 -3.71 9.28M

BiVictriX Therapeutics PLC BiVictriX Director Dealing (1106E)

09/03/2022 7:01am

UK Regulatory


Bivictrix Therapeutics (LSE:BVX)
Historical Stock Chart


From Mar 2021 to Mar 2024

Click Here for more Bivictrix Therapeutics Charts.

TIDMBVX

RNS Number : 1106E

BiVictriX Therapeutics PLC

09 March 2022

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

9 March 2022

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company")

Director Dealing

Alderley Park, 9 March 2022 BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, today announces the following dealing in the Company's ordinary shares of 1 pence each ("Ordinary Shares").

On 8 March 2022, 100,000 Ordinary Shares at a price of 22.25 pence each were purchased by Iain Ross, Chairman of the Company, through his self-invested personal pension (SIPP).

Following this purchase, Mr Ross is benefically interested in 400,000 Ordinary Shares representing 0.61 per cent of the Company's total issued share capital.

-Ends-

 
 For more information, please contact: BiVictriX Therapeutics plc 
   Tiffany Thorn, Chief Executive Officer       Email: info@bivictrix.com 
    Iain Ross, Chairman 
   SP Angel Corporate Finance LLP (NOMAD 
    and Broker)                                  Tel: +44 (0) 20 3470 
                                                 0470 
   David Hignell, Caroline Rowe (Corporate 
    Finance) 
    Vadim Alexandre, Rob Rees (Sales and 
    Broking) 
   Panmure Gordon (UK) Limited (Joint Broker)   Tel: +44 (0) 20 7886 2500 
   Rupert Dearden/Freddy Crossley/Emma Earl 
    Consilium Strategic Communications 
   Mary-Jane Elliott, Genevieve Wilson,         Tel: +44 (0) 20 3709 5700 
    Alex Gunter                                  Email: Bivictrix@consilium-comms.com 
 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst eliminating treatment-related toxicities.

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni(R) therapeutics which are designed to selectively target antigen co-expression fingerprints, or "twin antigens", on tumour cells, which are largely absent from healthy cells. Whereas this concept has been validated in a clinical diagnostic setting to support the diagnosis and monitoring of haematological cancers, it has not yet been widely used in a therapeutic setting.

BiVictriX has identified a diverse panel of novel cancer-specific "twin antigens", across a broad range of cancer indications including Diffuse Large B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm. The Company is using these novel "twin-antigens" to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and currently constitute areas of high unmet medical need.

Find out more about BiVictriX online at www.bivictrix.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1.   Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                                              Iain Ross 
     -------------------------------  -------------------------------------- 
 2.   Reason for the Notification 
     ----------------------------------------------------------------------- 
 a)   Position/status                  Non-Executive Chairman 
     -------------------------------  -------------------------------------- 
 b)   Initial notification/Amendment   Initial notification 
     -------------------------------  -------------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ----------------------------------------------------------------------- 
 a)   Name                             BiVictriX Therapeutics plc 
     -------------------------------  -------------------------------------- 
 b)   LEI                              213800ZI85IZNA6N3L53 
     -------------------------------  -------------------------------------- 
 4.   Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ----------------------------------------------------------------------- 
 a)   Description of                   Ordinary Shares of 1 pence each 
       the Financial                    GB00BNXH3K91 
       instrument, type 
       of instrument 
      Identification 
       code 
     -------------------------------  -------------------------------------- 
 b)   Nature of the                    Purchase of Ordinary Shares via 
       transaction                      SIPP 
     -------------------------------  -------------------------------------- 
 c)   Price(s) and                       Price(s)   Volume(s) 
       volume(s)                          22.25 p    100,000 
                                                    ---------- 
     -------------------------------  -------------------------------------- 
 d)        Aggregated information:      Price(s)                  Volume(s) 
             *    Aggregated volume                       22.25p   100,000 
                                                                  ---------- 
 
             *    Price 
     -------------------------------  -------------------------------------- 
 e)   Date of the transaction          8 March 2022 
     -------------------------------  -------------------------------------- 
 f)   Place of the                     AIM, London Stock Exchange 
       transaction 
     -------------------------------  -------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHDDGDXCBGDGDI

(END) Dow Jones Newswires

March 09, 2022 02:01 ET (07:01 GMT)

1 Year Bivictrix Therapeutics Chart

1 Year Bivictrix Therapeutics Chart

1 Month Bivictrix Therapeutics Chart

1 Month Bivictrix Therapeutics Chart

Your Recent History

Delayed Upgrade Clock